Praxis Precision Medicines, Inc.

Praxis reported Q2 operating expenses of $96.9 million, including $69.4 million of R&D and $27.5 million of G&A, versus $76 million of operating expenses in Q2 2025. Operating cash usage was $78 million in the quarter versus $55 million a year ago. The company ended Q2 with $1.4 billion in cash, cash equivalents and marketable securities, up from $926 million at December 31, 2025, and said that is enough to fund runway into 2028. For guidance, management said G&A will increase in the second half of the year to support upcoming launches, and reiterated that ulixacaltamide and relutrigine are both in late-stage FDA review with approvals expected in about six months; relutrigine’s new PDUFA target is December 27, and ulixacaltamide is expected by January next year.

Marcio Souza framed the quarter as the moment Praxis shifted from planning to becoming a commercial company, emphasizing that the organization is now building for two near-term launches. He highlighted positive FDA interactions, saying there were no efficacy-related significant issues for ulixacaltamide, no AdCom planned, and no findings from the comprehensive BIMO inspection. His tone was very optimistic and often emphatic, especially on the potential to serve patients with no approved treatments and on the company’s readiness to launch ahead of PDUFA.

Tim Kelly focused on the buildout behind the commercial transition and the quarter’s spending trends. He cited Q2 operating expenses of $96.9 million, operating cash use of $78 million, and cash resources of $1.4 billion at quarter-end versus $926 million at year-end 2025. He said the cash runway remains adequate into 2028 and warned that G&A will rise in the second half as Praxis adds commercial field teams, runs disease-awareness campaigns, builds inventory, and strengthens business systems and infrastructure.

Analysts pressed on FDA review dynamics, launch readiness, payer access, sales force sizing, and whether titration or labeling changes could improve ulixacaltamide persistence. Management said the FDA discussions were broad but straightforward, that titration came up as expected, and that they believe patients who stay on therapy longer are more likely to tolerate and benefit from it; they also described a planned 'hub of the future' to support the first prescription and early titration. On relutrigine, questions centered on whether EMERALD is enriched for sodium-channel-responsive patients and whether broader DEE biology could dilute efficacy; management said the cohort includes patients with pharmacosensitive mechanisms, that severe seizure burden makes placebo response low, and that they expect consistent positive activity across etiologies, though not necessarily identical responses. In commercial questions, Praxis said ulixacaltamide’s neurologist target list is about 13,000 to 15,000, implying a field force of around 300, and reiterated a pricing framework that they believe remains in the $50,000 to $100,000 annual range, though they did not disclose a final price.